Dendritic cells play a central role in controlling immunity. Antigen is initially processed by immature DCs, which subsequently undergo maturation involving phenotypic and functional changes that enable DC to mediate specific T and B cell activation in a highly effective manner. In tumor-bearing hosts, antitumor immunity can be compromised because tumor antigens fail to elicit immune mechanisms to resist tumor growth. This outcome is possibly related to a deficiency of DC expressing tumor antigens. Accordingly, strategies to vaccinate against tumor-specific antigens utilizing DC are being developed to bolster anti-tumor immunity. 
Dendritic cells play a central role in controlling immunity. Antigen is initially processed by immature DCs, which subsequently undergo maturation involving phenotypic and functional changes that enable DC to mediate specific T and B cell activation in a highly effective manner. In tumor-bearing hosts, antitumor immunity can be compromised because tumor antigens fail to elicit immune mechanisms to resist tumor growth. This outcome is possibly related to a deficiency of DC expressing tumor antigens. Accordingly, strategies to vaccinate against tumor-specific antigens utilizing DC are being developed to bolster anti-tumor immunity. 1 Loading of DC with antigens can be achieved by incubation with antigen-specific peptides 2, 3 or cell lysates. 3 Alternatively, antigen expression in DC can be induced by gene transfer using either RNA 4 or DNA with nonviral 1, 5 or viral 1, 6 vectors. Among the viral vectors, Ad is notable for efficient in vitro and in vivo gene transfer and expression, which is independent of target cell replication. However, the relative resistance of DCs to Ad infection due to lack of CAR expression on DC surface is an ostensible shortcoming for this approach. Efficient DCs transduction with Ad has been reported, but high viral doses and prolonged exposure of the DCs to virus were required. 8 Ad transduction can also be facilitated with liposomes, 9 but toxicity for DCs is a potential problem. Thus, there is a need to improve the specificity of targeting Ad vectors to DC in the gene therapy field.
A recently reported approach to achieve directed Adbased gene transfer to DCs utilized a chimeric Ad of serotype 5 in which the fiber knob region was replaced with that of Ad of serotype 35. 10 However, optimal transduction efficiency with such chimeric virus required a high virus-to-cell ratio (multiplicity of infection, MOI). An alternative approach of Ad targeting to DCs was developed in our laboratory using a chemical conjugate comprising a F(Ab) fragment of a monoclonal antibody raised against Ad serotype 5 fiber and a whole mAb against the DC marker protein CD40. 7 This bispecific antibody demonstrated high transduction efficiency of DCs at much lower viral doses. Notably, this DC-targeted, Ad infection strategy also lead to phenotypic changes reflecting DC maturation.
Recombinant proteins offer a number of technological advantages including simplified production and purification when compared with chemical conjugates. In addition, during chemical conjugation only a fraction of the input component will yield a functionally active bispecific molecule due to the inherent variability of the technique. A product intended for clinical use should have a strictly defined and reproducible composition. Recombinant proteins achieve this by rational design. We have recently described an approach of bispecific adaptor-based Ad targeting with a recombinant protein consisting of an extracellular portion of Ad receptor CAR fused to epidermal growth factor (EGF). 11 In that study, the CAR/EGF fusion protein specifically directed Ad infection to EGF receptor expressing cells that lacked expression of CAR. In the present study, our aim was to create a fusion protein between CAR and a single chain antibody against human CD40 (Figure 1 ). We hypothesized that such a recombinant CAR-anti-CD40scFv protein would facilitate efficient, specific DCs transduction with Ad.
The CAR/G28 fusion protein was generated by the following scheme. Initially, the extracellular domain of human CD40 (hCD40ecto, including amino acids , numbered according to Ref. 12) was produced in a prokaryotic expression system and purified. The anti-CD40 single chain Fv cDNA was generated from the G28-5 hybridoma cell line. 13 The hCD40ecto was then used to screen for CD40-specific scFv. The G28-5 scFv cDNA was linked to that of the CAR ecto-domain replacing the EGF portion in the CAR/EGF fusion protein. 11 Finally, the CAR/G28 fusion protein was produced using recombinant baculovirus, purified and characterized. Recombinant hCD40ecto was produced in a prokaryotic expression system to facilitate anti-CD40 scFv and CAR/scFv isolation and validation. The hCD40ecto gene fragment was PCR-amplified from a cDNA clone generously provided by Dr I Stamenkovic (Molecular Pathol- ogy Unit, Massachusetts General Hospital and Department of Pathology, Harvard Medical School, Boston, MA, USA). Next, the hCD40ecto cDNA was subcloned into the pET21a plasmid and expressed in BL21(DE) E. coli. The hCD40ecto recombinant protein of 19 kDa was purified from the cell lysate and its identity confirmed by immunobloting with polyclonal antibody sc-974 and mAb G28-5 against human CD40 (Figure 2a) .
Figure 2 Fusion proteins production and characterization. (a) Production
The gene segments coding for VH and VL of the G28-5 mAb were PCR-amplified from the corresponding hybridoma cDNA and ligated with a Yol linker by twostep cloning into pSEX81 14 phagemid, thus creating a miniphage display library that facilitated anti-CD40 scFv isolation. The library was screened using hCD40ecto as described. 15 Positive clones were identified in ELISA, and primary DNA structure of the scFv gene was confirmed by sequencing. Single chain Fv G28-5 cDNA was recloned into expression vector pOPE101 16 used to produce scFv G28-5 of approximately 29 kDa in E. coli. Purification of scFv was performed with Ni-NTA as described 17 ( Figure 2b ). The ability of scFv G28-5 to specifically bind hCD40ecto was demonstrated in ELISA (data not shown).
To generate the CAR/G28 fusion protein, scFv G28-5 cDNA was cloned in-frame with that of CAR, generating the pFBsCARslG28 plasmid, which was then used for baculovirus genome generation. Our attempts to express CAR/G28 cDNA in various bacterial expression systems failed due to massive protein degradation (data not shown). The baculovirus genome containing the CAR/G28 cDNA was used to transfect Sf-9 insect cells and the resultant baculovirus was used for larger scale infection of High Five cells. The recombinant fusion protein was produced and purified from 1 liter of super- 
cells/experimental point) at MOI of 100 or 500, respectively. The virus was pre-incubated with indicated amounts of CAR/G28, before mixing with MDDCs. Transduced MDDCs were analyzed for GFP expression by flow cytometry to measure increased fluorescence intensity (a) or Luc content (b,c) by luminometry to measure relative light units (RLU). Specificity of transduction was demonstrated by inhibition of infection with G28-5 hybridoma supernatant. Mock, RhMDDCs were treated with neither virus, nor fusion protein; Ad only, RhMDDCs were treated with Ad without the fusion protein.
Gene Therapy natant of infected cell culture. Purified recombinant fusion protein had the expected molecular weight of 54 kDa as demonstrated by immunoblot with anti-CAR antibodies (Figure 2c ). The level of the fusion protein production was approximately 2 mg/l of culture. Specificity of the CAR/G28 towards both recombinant hCD40ecto and Ad5 fiber 18 knob was demonstrated in ELISA ( Figure  2d) . After confirming the dual specificity of CAR/G28, we examined the recombinant protein for its ability to target Ad infection to DCs of rhesus monkey or human origin. Adenoviruses bearing luciferase (Luc) or green fluorescent protein (GFP) as transgenes were used in the DC transduction experiments.
Rhesus monocyte-derived DCs (RhMDDC) were derived from heparinized peripheral mononuclear cells isolated by gradient centrifugation. Monocytes were enriched to a purity of >80% by adherence to anti-CD14 coated magnetic microbeads and cultured in RPMI containing autologous plasma and cytokines recombinant human GM-CSF and IL-4 as described. 19 The phenotype of MDDCs was assessed by staining for HLA-DR, CD83, CD80 and CD86 with corresponding anti-human antibodies that cross-react with rhesus macaque (data not shown). The RhMDDCs were infected with Ad at MOI of 100 p.f.u./cell (optimal viral dose determined in Ref. 7) in the presence and absence of CAR/G28. Infection efficiency was assessed by measuring the transgene expression. As shown in Figure 3 , both luciferase and GFP activity were significantly higher when the Ad infection was mediated by CAR/G28. The fusion protein enhanced DC transduction in a dose-dependent manner (Figure 3a, b) . Of note, doses of CAR/G28 higher than 100 ng per 2.5 × 10 4 DCs caused further transgene expression enhancement, but some cell toxicity was observed at those doses (data not shown). This toxicity effect is probably associated with an unknown effect of soluble CAR. Pre-treatment of DCs with G28-5 hybridoma supernatant efficiently blocked the infection (Figure 3c ), indicating that Ad infectivity enhancement was due to engagement of CD40 for virus docking. These results suggest that the dual (human and rhesus) reactivity of CAR/G28 provides an advantage for DC-based vaccine approaches using gene therapy in the nonhuman primate model.
We also evaluated Ad transduction of human DCs with CAR/G28 fusion protein. Human monocytederived (HMDDC) were obtained by gradient centrifugation followed by plastic adherence enrichment and cultivation in the presence of cytokines. 20 The HMDDCs were infected with Ad in the presence and absence of indicated amounts of CAR/G28. The ability of CAR/G28 to enhance Ad infectivity towards human DCs was examined with adenovirus vectors bearing either Luc or GFP reporter genes. GFP expression was assessed by direct fluorescence microscopy, whereas the Luc expression was indirectly measured on a luminometer. Data presented in Figure 4 demonstrate CAR/G28-mediated enhancement of Ad transgene expression assayed both qualitatively (Figure 4a -c) and quantitatively ( Figure 4e ). As a positive control, the Fab-␣-CD40 chemical conjugate 7 was used (Figure 4d, f) . Analysis of data presented in Figure 4 suggests that the CAR/G28 fusion protein achieves similar levels in promoting DC transduction compared with the Fab-␣-CD40 chemical conjugate.
In summary, we describe here a novel recombinant fusion protein designed to promote specific adenovirusmediated transduction of DCs. After examining prokaryotic and eukaryotic expression systems, we achieved acceptable levels of CAR/G28 recombinant fusion protein production using baculovirus-infected insect cells. The fusion protein has a polyhistidine tag, allowing efficient purification. From the production standpoint, this feature makes the recombinant fusion protein superior in comparison to the anti-Ad:anti-CD40 bispecific antibody Fab-␣-CD40 prepared by chemical conjugation. We have demonstrated recently the feasibility of a CAR-ligand fusion protein as an efficient Ad targeting moiety. 11 The present work expands the utility of this kind of CAR-containing molecular adaptor to a new level with scFvs as a fusion partner. Current gene engineering technology allows generation of scFvs against virtually any antigen. The CAR/G28 fusion protein demonstrated the expected dual binding specificity and substantially enhanced Ad gene transfer to DCs (up to 200 times in some experiments compared with untargeted Ad). Monoclonal antibody G28-5 has been shown to be internalized upon CD40 binding. 21 Therefore, we have reason to believe that this internalization process can be involved in CD40-targeted Ad infection of DCs mediated by CAR/G28, in addition to normal, integrin-dependent, viral entry to cells. From a functional perspective, the fusion protein has been tested in two distinct experimental systems using rhesus monkey and human DCs. The cross-reactivity of the CAR/G28 fusion protein with CD40-positive human and monkey DCs resulted in marked enhancement of Ad infection in both systems. These data establish the feasibility of using the nonhuman primate rhesus macaque model for preclinical studies with CAR/G28 to advance gene therapy-based DC vaccine development. In both systems the fusion protein demonstrated outstanding ability to target Ad vectors to DCs efficiently and specifically. The development of CAR/G28 presents an opportunity to improve existing Ad-based approaches to genetically modify DCs for the treatment of human diseases.
